pipe, you and I both know RapiMeds will be here. When, it doesn't matter, it will be huge when it starts rolling. RapiMeds has been Mr. Schneiderman's baby since day one of SCRC inception. He has never given up on it. That's enough for me. I still believe if there is a reason to invest in SCRC it is RapiMeds. Mr. Schneiderman stated in a live interview that he feels RapiMeds will mirror compounding's success. These two revenue streams alone will eventually combine to make SCRC a $100M success story. There are branded pharma companies out there who would love to have $100M in revenues. SCRC will be enormous.